FACT CHECK: No, Scientists Did Not Find A New Cure For AIDS That Costs $40K
A post on Facebook claims that a new cure for Acquired immunodeficiency syndrome (AIDS) has been discovered and will cost $40 ...
STAT2h
Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more
Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...
News244h
Data rules: How numbers turned our HIV plans
Numbers put us in the know. We saw that with COVID-19, and now again, with Rwanda snuffing out the Marburg virus outbreak in ...
The Guardian Nigeria13h
‘Twice-yearly injection of Lenacapavir can reduce HIV risk’
A new study has revealed that daily oral antiretrovirals, like Truvada, are highly effective at preventing HIV when taken consistently alongside regular medical check-ups but their efficacy ...
Lenacapravir treats and prevents HIV, it does not cure infection | Fact check
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
Politifact20h
This drug helps manage infections and prevent AIDS, but claims it’s a ‘cure’ are not supported
"Currently, there is no therapeutic cure for HIV," Sheryl Zwerski, who holds a Doctor of Nursing Practice and directs the Prevention Sciences Program at the National Institute of Allergy and ...
Lenacapavir treats and prevents HIV, it does not cure infection | Fact check
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
STAT22h
Gilead to test once-a-year HIV prevention shot
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
batimes1d
Argentina’s HIV/AIDS fight advances, but experts warn more to be done
More than 5,000 people diagnosed with HIV each year in Argentina, with 98% of all infections a result of unprotected sex.
Gilead Sciences’ Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...
Sell Rating for GlaxoSmithKline Amidst Competitive Pressures from Gilead in HIV Market
Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...
ugandaradionetwork2d
Licensing, Cost Could Hinder Access to Lenacapavir
Lenacapavir is an injection given to women every six months, which has proven to protect women, especially those at high risk of contracting the HIV virus. Dr. Flavia revealed that during their study ...